Gunnar Schalasta
Overview
Explore the profile of Gunnar Schalasta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Exler S, Daiminger A, Grothe M, Schalasta G, Enders G, Enders M
J Clin Virol
. 2019 Jun;
117:33-36.
PMID: 31176209
Background: Due to its ease of collection saliva was recently recommended as the preferred specimen, not only for screening, but also for diagnosis of congenital cytomegalovirus (CMV) infection. Objective: To...
2.
Wiesmann F, Ehret R, Naeth G, Daumer M, Fuhrmann J, Kaiser R, et al.
J Clin Microbiol
. 2018 Aug;
56(10).
PMID: 30068537
High accuracy and precision at the lower end of quantification are crucial requirements of a modern HIV viral load (VL) assay, since some clinically relevant thresholds are located at 50...
3.
Schalasta G, Borner A, Speicher A, Enders M
Clin Chem Lab Med
. 2017 Dec;
56(4):634-641.
PMID: 29197859
Background: Proper management of patients with chronic hepatitis B virus (HBV) infection requires monitoring of plasma or serum HBV DNA levels using a highly sensitive nucleic acid amplification test. Because...
4.
Schalasta G, Speicher A, Borner A, Enders M
J Clin Microbiol
. 2016 Feb;
54(4):1101-7.
PMID: 26865682
Quantitating the level of hepatitis C virus (HCV) RNA is the standard of care for monitoring HCV-infected patients during treatment. The performances of commercially available assays differ for precision, limit...
5.
Schalasta G, Borner A, Speicher A, Enders M
Clin Chem Lab Med
. 2015 Sep;
54(3):493-9.
PMID: 26351942
Background: Quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma has become the standard of care in the management of HIV-infected patients. There are several commercially available assays...
6.
Enders M, Klingel K, Weidner A, Baisch C, Kandolf R, Schalasta G, et al.
J Clin Virol
. 2010 Aug;
49(3):163-8.
PMID: 20729141
Background: Risk assessment of parvovirus B19 (B19)-associated fetal complications following gestational B19 infection remains controversial. Objectives: To determine the risk of fetal hydrops or non-hydropic late intrauterine fetal death following...
7.
Enders M, Lindner J, Wenzel J, Baisch C, Schalasta G, Enders G, et al.
J Clin Virol
. 2009 May;
45(4):300-3.
PMID: 19473872
Background: Human bocavirus (HBoV) is a recently identified parvovirus associated with respiratory disease in infants. Animal bocaviruses have been shown to cause intrauterine infection, fetal anasarca and abortion in late...
8.
Schalasta G, Rosenthal T, Grothe M
Clin Lab
. 2007 Apr;
53(3-4):131-3.
PMID: 17447648
Background: Persistent infection with high risk human papillomavirus (HR-HPV) types is at the origin of cervical cancer in women and HPV-genotyping is considered to be a valuable tool for risk...
9.
Enders M, Schalasta G, Baisch C, Weidner A, Pukkila L, Kaikkonen L, et al.
J Clin Virol
. 2005 Dec;
35(4):400-6.
PMID: 16332455
Background: Over 95% of fetal complications (fetal hydrops and death) occur within 12 weeks following acute parvovirus B19 (B19) infection in pregnancy. Therefore, weekly fetal ultrasound monitoring is generally recommended...
10.
Eisenbach C, Longerich T, Fickenscher H, Schalasta G, Stremmel W, Encke J
J Clin Virol
. 2005 Sep;
35(1):109-12.
PMID: 16185915
Background: We report hepatitis A virus (HAV) infection of a liver allograft following transplantation for fulminant liver failure due to HAV infection. This rare condition has been described in only...